Sökning: WFRF:(Harris Robert A) > (2010-2014) > Intranasal Delivery...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03617naa a2200421 4500 | |
001 | oai:DiVA.org:uu-223631 | |
003 | SwePub | |
008 | 140423s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2236312 URI |
024 | 7 | a https://doi.org/10.1111/imm.122752 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Fransson, Moau Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)moafr634 |
245 | 1 0 | a Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis |
264 | c 2014-06-10 | |
264 | 1 | b Wiley,c 2014 |
338 | a print2 rdacarrier | |
500 | a De två första författarna delar förstaförfattarskapet. | |
520 | a Treatment with mesenchymal stromal cells (MSC) is currently of interest for a number of diseases including multiple sclerosis (MS). MSCs is well known to target inflamed tissues however, in a therapeutic scenery, systemic administration will lead to few cells reaching the brain. We hypothesized that MSCs may target the brain upon intranasal (i.n) administration and persist in CNS tissue if expressing a CNS-targeting receptor. To demonstrate proof of concept, MSCs were genetically engineered to express a myelin oligodendrocyte glycoprotein (MOG)-specific receptor. Engineered MSCs retained their immunosuppressive capacity, infiltrated into the brain upon i.n. cell administration, and were able to significantly reduce disease symptoms of experimental autoimmune encephalomyelitis (EAE). The mice treated with CNS-targeting MSCs were resistant to further EAE induction whereas non-targeted MSC did not give such persistent effects. Histological analysis revealed increased brain restoration in engineered MSC-treated mice. In conclusion, MSCs can be genetically engineered to target the brain and prolong therapeutic efficacy in an EAE model. | |
650 | 7 | a NATURVETENSKAPx Biologix Immunologi0 (SwePub)106052 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Biological Sciencesx Immunology0 (SwePub)106052 hsv//eng |
700 | 1 | a Piras, Elenau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)elpir677 |
700 | 1 | a Wang, Haou Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab4 aut |
700 | 1 | a Burman, Joachimu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab,Neurologi4 aut0 (Swepub:uu)joabu293 |
700 | 1 | a Duprez, Idau Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab4 aut |
700 | 1 | a Harris, Robert A4 aut |
700 | 1 | a Leblanc, Katarina4 aut |
700 | 1 | a Magnusson, Peetra Uu Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk immunologi4 aut0 (Swepub:uu)petrmagn |
700 | 1 | a Brittebo, Evau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)evabritt |
700 | 1 | a Loskog, Angelica S Iu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)angelosk |
710 | 2 | a Uppsala universitetb Klinisk immunologi4 org |
773 | 0 | t Immunologyd : Wileyg 142:3, s. 431-441q 142:3<431-441x 0019-2805x 1365-2567 |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imm.12275 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-223631 |
856 | 4 8 | u https://doi.org/10.1111/imm.12275 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.